Meniscus Tear Market Growth Anticipated by 2032 | Companies includes Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation

The Meniscus Tear market growth is expected due to increased interest from companies in developing new treatments, advancements in diagnostic methods, and the anticipated introduction of emerging therapies during the forecast period.
The market for meniscus tears is projected to experience significant growth from 2019 to 2032, according to the latest report titled "Meniscus Tear Market Insights, Epidemiology, and Market Forecast 2032 [https://www.delveinsight.com/report-store/meniscus-tear-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" by DelveInsight.

The report provides a comprehensive overview of current treatment practices for meniscus tears, highlights upcoming drugs in the pipeline, and details the market shares of various therapies. It also outlines the anticipated trajectory of the meniscus tear market from 2019 to 2032 across the 7MM (the United States, EU-4 countries-Italy, Spain, France, and Germany-the United Kingdom, and Japan).

Driving Forces Behind the Meniscus Tear Market Growth

The primary driver behind the growth in the meniscus tear market size is the increasing number of incidents and prevalent cases.

Discover the Anticipated Evolution and Growth of the Market @ Meniscus Tear Therapeutics Market Forecast [https://www.delveinsight.com/report-store/meniscus-tear-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Therapeutic Advancements and Emerging Treatments:

*
Meniscus Tear Clinical Trial Progression: The market is poised for substantial growth, fueled by the anticipated launch of emerging therapies between 2023 and 2032. Leading companies such as Smith & Nephew, Arcuro Medical, Zimmer Biomet Holdings, and others are actively developing innovative treatments for potential introduction to the market.

*
Meniscus Tear Innovative Therapies: Ongoing research and development efforts are advancing the introduction of innovative devices aimed at addressing the signs and symptoms of meniscus tears. Medical devices such as the NOVOSTITCH PRO Meniscal Repair System, JuggarStitch, and the SuperBall Meniscus Repair System, among others, are driving growth in the meniscus tear market.

Meniscus Tear Market Dynamics

Smith & Nephew developed the FAST-FIXm, a meniscal repair method renowned for its durability, consistency, and efficiency. Biomechanical studies have shown that the vertical mattress suture performed with the FAST-FIX 360 Meniscal Repair System achieves biomechanical characteristics comparable to those of similar sutures executed using open and inside-out techniques.

In September 2020, Smith & Nephew launched the NOVOSTITCH PRO Meniscal Repair System in Europe after successfully obtaining CE mark certification. This system expands repair options for approximately 600,000 European patients annually who previously had only the option of meniscal removal. The NOVOSTITCH PRO Meniscal Repair System is also commercially available in the US, Europe, the Middle East, Africa, and selected other countries.

Zimmer Biomet Holdings received FDA clearance in September 2019 for the JuggerStitch meniscal repair device. This advanced technology, representing the next generation of meniscus repair tools, has achieved 510(k) clearance and is now available in the US market. The JuggerStitch features a unique design with two soft anchors connected by a knotless, self-locking suture loop, which aims to enhance tissue preservation and provide surgeons with better control over tissue compression compared to traditional sliding knot implants.

Additionally, in June 2020, Arcuro Medical received FDA approval for its SuperBall Meniscus Repair System.

Meniscus Tear Treatment Market [https://www.delveinsight.com/report-store/meniscus-tear-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

The therapeutic management of meniscus tears primarily involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs), which help alleviate pain and reduce swelling around the knee. Unfortunately, there is no pharmacological cure for this condition.

Current medical management for meniscus tears is often considered insufficient. However, the effectiveness of treatment can be greatly improved through the use of existing diagnostic, therapeutic, and preventative measures, as well as surgical interventions. Biologics, which are medicines derived from biological sources such as blood, bone marrow, and fat cells, represent an emerging technology. They hold potential as a complementary approach to nonsurgical treatments by aiding tissue repair and reducing knee inflammation.

According to DelveInsight, the meniscus tear market in the 7MM is expected to undergo significant changes during the study period from 2019 to 2032.

Leading Meniscus Tear Companies and Emerging Drugs: Leading companies like Smith & Nephew, Arcuro Medical, and Zimmer Biomet Holdings, among others, are actively working on developing innovative treatments for potential entry into the meniscus tear market.

Meniscus Tear Therapeutic Landscape: Medical devices used for treating meniscus tears include the NOVOSTITCH PRO Meniscal Repair System, JuggarStitch, SuperBall Meniscus Repair System, and others.

Meniscus Tear Overview:

A meniscus tear is an injury to one of the rubbery cartilage bands in the knee that act as shock absorbers. This type of tear can occur suddenly when the knee is twisted while the foot is fixed on the ground, or it can develop gradually as the meniscus loses its elasticity, leading to frayed edges. Meniscus tears are common knee injuries, particularly among athletes and recreational sports enthusiasts, as well as older individuals and those with arthritis. Symptoms typically include pain, swelling, stiffness, and difficulty extending the knee. Depending on the severity of the tear, surgery may or may not be required.

Diagnosis of a meniscus tear often begins with a physical examination, but may also involve imaging tests such as MRI, X-rays, and arthroscopy.

Management of a meniscus tear depends on factors such as the patient's age, symptoms, and activity level. Treatment options are categorized into nonsurgical and surgical approaches. Nonsurgical treatments include rest, ice, compression, and elevation; medications to relieve pain; physical therapy; corticosteroid injections; and biologic injections. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen can help reduce inflammation and pain, while acetaminophen manages pain without addressing inflammation. Corticosteroids, though not healing the tear, can reduce swelling and discomfort when injected directly into the knee. Biologics, which are derived from biological sources such as blood, bone marrow, and fat cells, represent an emerging technology that may complement nonsurgical treatments by promoting tissue healing and reducing inflammation.

Key Facts Meniscus Tear Market Report:

*
Key players such as Smith & Nephew, Arcuro Medical, Zimmer Biomet Holdings, and others are investigating its candidates for Meniscus Tear.

*
Meniscus Tear pipeline includes the devices as NOVOSTITCH PRO Meniscal Repair System, JuggarStitch, SuperBall meniscus repair system, and others.

*
Due to the positive results from key players in the meniscus repair systems market, such as Zimmer Biomet, Smith & Nephew, and Arcuro Medical, leading manufacturers are advancing their expertise with integrated technologies.

*
Meniscal injuries are common, affecting approximately 61 individuals per 100,000, with a prevalence rate between 12% and 14%. The risk of meniscal tears increases significantly when accompanied by an anterior cruciate ligament (ACL) injury, with rates ranging from 22% to 86%. In the United States, out of an estimated 850,000 cases annually, about 10% to 20% of orthopedic surgeries involve meniscus repair. Acute meniscal tears are most frequently seen in men aged 21 to 30 and women aged 11 to 19, with a male-to-female ratio of 2.5:1 to 4:1. Conversely, degenerative meniscal tears are more common in men aged 40 to 60 years.

*
The meniscus tear market is projected to experience steady growth throughout the forecast period (2023-2032), driven by the rising incidence of sports injuries, growing awareness of advanced medical technologies, and an increase in osteoarthritis cases, all of which are expected to boost revenue.

*
DelveInsight analysts have noted a recent significant rise in meniscus tear cases. Advances in scientific research and breakthrough discoveries are anticipated to further stimulate market growth by introducing new therapeutic options.

*
Several companies, including FUJIFILM Toyama Chemical Co., Ltd., are actively developing drugs in early to mid-phase clinical trials. With the expected approval of these innovative therapies during the forecast period, the overall therapeutic market for meniscus tears is projected to see substantial growth, reflecting a strong compound annual growth rate (CAGR).

Meniscus Tear Epidemiology Segmentation:

*
According to Luvsannyam et al. (2022), the incidence of meniscal tears in the US is estimated at 60 per 100,000 people, with a significant rise in related injuries attributed to increased sports participation and advancements in diagnostic technology.

*
Masini et al. (2015) reported that, from 2005 to 2012, there were 79 cases of meniscus tears in stable knees among a cohort of 9,086 subjects. Of these, 68 cases (86%) were in males and 11 cases (14%) were in females.

*
Leitao et al. (2022) identified several risk factors that elevate the likelihood of meniscal tears. Notably, non-modifiable risk factors include sex, with men experiencing meniscal tears at a rate 2.5 times higher than women.

*
Bubnis et al. (2023) found that men over the age of 40 are also at increased risk for meniscal tears.

The Meniscus Tear market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

- Total Prevalence of Meniscus Tear

- Gender-specific Prevalence of Meniscus Tear

- Type-specific Prevalence of Meniscus Tear

- Age-specific Prevalence of Meniscus Tear

- Diagnosed Cases of Meniscus Tear

DelveInsight's comprehensive report provides a thorough exploration of the Meniscus Tear market, covering key Meniscus Tear players, emerging Meniscus Tear therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Meniscus Tear Market Outlook 2032 [https://www.delveinsight.com/sample-request/meniscus-tear-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Meniscus Tears Emerging Therapy Assessment

The dynamics of the meniscus tear market are expected to evolve significantly in the coming years due to advancements in research and development. The launch of new devices is anticipated throughout the forecast period.

Ceterix Orthopaedics, now acquired by Smith & Nephew, completed the STITCH trial, the first prospective multicenter investigation of suture-based repair for horizontal meniscus tears, a common knee injury. The trial, last updated in December 2020 on clinicaltrials.gov, reported positive results in March 2021. The study involved 23 patients with 2-year follow-up data. Freedom from reoperation was 96.0% at 6 months (26/27), 91.7% at 1 year (23/25), and 82.6% at 2 years (19/23). Significant improvements were observed from baseline at 2 years for IKDC (36.7 to 82.5; P < .001), Knee Injury and Osteoarthritis Outcome Score (52.2 to 89.3; P < .001), Lysholm (50.2 to 87.4; P < .001), and Tegner scores (3.3 to 5.3; P = .007). The minimal clinically important difference was met or exceeded for IKDC and Lysholm scores in 69.2% and 65.4% of patients, respectively. Four patients (6.7%) experienced serious complications, two of which were deemed related to the procedure.

Ortho Regenerative Technologies is developing RESTORE-M, aimed at increasing the number of meniscus repair procedures while reducing meniscectomy procedures. The product, Ortho-M, will be placed into the lesion before it is repaired using the appropriate physical fixation technique. The company plans to complete preclinical studies by 2021 and begin Phase I/II trials.

Request for a sample report @ https://www.delveinsight.com/sample-request/meniscus-tear-market [https://www.delveinsight.com/sample-request/meniscus-tear-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=meniscus-tear-market-growth-anticipated-by-2032-companies-includes-merck-teva-pharmaceutical-lipella-pharmaceuticals-seikagaku-corporation]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.